Renzapride

From WikiMD.org
Jump to navigation Jump to search

Renzapride

Renzapride (/rɛnˈzæpraɪd/) is a gastroprokinetic agent and antiemetic which was developed by Alizyme plc but is no longer being actively researched. It acts as a 5-HT4 receptor agonist and 5-HT3 receptor antagonist. The drug was under development for the treatment of gastrointestinal disorders, but development was discontinued due to concerns about side effects and efficacy.

Etymology

The term "Renzapride" is derived from the combination of the words "ren" and "zapride". "Ren" is a prefix often used in the naming of drugs to indicate their action on the renal system, while "zapride" is a suffix used in the naming of drugs that act on the serotonin system.

Related Terms

  • Gastroprokinetic agent: A type of drug that increases the movements or contractions of the stomach and intestines.
  • Antiemetic: A drug that is effective against vomiting and nausea.
  • 5-HT4 receptor: A type of receptor in the body that is activated by the neurotransmitter serotonin.
  • 5-HT3 receptor: Another type of receptor in the body that is also activated by serotonin.
  • Gastrointestinal: Relating to the stomach and the intestines.

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski